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Objectives: Constitutive overexpression of patAB has been observed in several unrelated fluoroquinolone-
resistant laboratorymutants and clinical isolates; therefore, we sought to identify the cause of this overexpression.
Methods: Constitutive patAB overexpression in two clinical isolates and a laboratory-selected mutant was investi-
gated using a whole-genome transformation approach. To determine the effect of the detected terminator muta-
tions, theWTandmutated patA leader sequences were cloned upstream of a GFP reporter. Finally, mutation of the
opposing base in the stem–loop structure was carried out.
Results:We identified three novel mutations causing up-regulation of patAB. All three of these were located in the
upstream region of patA and affected the same Rho-independent transcriptional terminator structure. Eachmuta-
tionwas predicted to destabilize the terminator stem–loop to a different degree, and therewas a strong correlation
between predicted terminator stability and patAB expression level. Using a GFP reporter of patA transcription, these
terminator mutations led to increased transcription of a downstream gene. For one mutant sequence, terminator
stability could be restored by mutation of the opposing base in the stem–loop structure, demonstrating that tran-
scriptional suppression of patAB is mediated by the terminator stem–loop structure.
Conclusions: This study showed that amutation in a Rho-independent transcriptional terminator structure confers
overexpression of patAB and fluoroquinolone resistance. Understanding how levels of the PatAB efflux pump are
regulated increases our knowledge of pneumococcal biology and how the pneumococcus can respond to various
stresses, including antimicrobials.
Keywords: multidrug resistance, efflux, antimicrobial resistance mechanisms, regulation
Introduction
Streptococcus pneumoniae is an important human pathogen
representing a major disease burden worldwide. It is the main
bacterial cause of community-acquired pneumonia, as well as
being the cause of severe invasive infections such as meningitis.
Fluoroquinolones are one of the classes of antibiotics frequently
used to treat pneumococcal disease.1 However, fluoroquinolone
resistance in pneumococci is easily selected and causes treat-
ment failures.2 Knownmechanisms of fluoroquinolone resistance
in pneumococci are target site mutations in topoisomerase
genes3,4 and the overexpression of the ABC transporter genes
patA and patB.5 –7 PatA and PatB dimerize to form a functional
ABC transporter that exports certain hydrophilic fluoroquinolones,
as well as other toxic compounds, such as the dye ethidium
bromide.8
As well as drug efflux, PatAB has also been implicated in reliev-
ing a fitness cost associated with linezolid resistance mutations9
and intolerance of pH stress.10 Up-regulation of patAB has also
been observed as the defining characteristic of ameningitis isolate
compared with a bloodstream isolate taken from the same
patient.11 These observations hint at a more fundamental role
for the patAB transporter in pneumococcal stress responses.
Elucidating the regulatory mechanisms controlling patAB may
provide further insight into the role of this transporter in the
pneumococcal cell. Specific regulators controlling expression of
# The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/
4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
J Antimicrob Chemother
doi:10.1093/jac/dku449
1 of 10
 Journal of Antimicrobial Chemotherapy Advance Access published November 18, 2014
 at U
niversity of Birm
ingham
 on January 19, 2015
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
patAB are unknown, but two previous studies have suggested that
expression of these genes is induced by exposure to sub-inhibitory
concentrations of fluoroquinolones and by DNA damage.12,13
In two independent studies, constitutive overexpression of
patAB was associated with a G–T mutation 46 bp upstream of
patA.9–11 This is predicted to affect folding of a Rho-independent
transcriptional terminator, and hypothesized to allow increased
transcriptional read-through into patA.11 In this study, we identified
three novel mutations affecting this putative terminator structure
in fluoroquinolone-resistant clinical isolates of S. pneumoniae with
constitutive overexpression of patAB. We investigated the effect of
these mutations on patA transcription using GFP reporter fusions,
and showed that transcriptional repression of GFP could be restored
by reconstituting the terminator base-pairing structure. This study
shows that attenuator mutations mediate clinically relevant over-
expression of patA(B) and fluoroquinolone resistance.
Materials and methods
Bacterial strains and growth
All S. pneumoniae strains and clinical isolates (Table 1) were grown
statically at 378C in an atmosphere of 5% CO2 in brain heart infusion
broth (BHI; Oxoid, Basingstoke, UK) or on Columbia agar (Oxoid,
Basingstoke, UK) supplemented with 5% defibrinated horse blood (TCS
Biosciences, Buckingham, UK). Bacterial growth in broth was assessed by
measurement of OD at 660 nm (OD660) of liquid cultures. Escherichia coli
strains used for plasmid construction were grown overnight on LB (Oxoid,
Basingstoke, UK) agar at 378C or in LB broth at 378C with shaking at
180 rpm.
DNA extraction and PCR
Genomic DNA was extracted from all strains using the Wizard Genomic
DNA extraction kit (Promega) following the manufacturer’s instructions.
The primer sequences and PCR conditions used in this study are listed in
Table 2.
Transformation
Transformation of S. pneumoniae R6 was carried out as described previ-
ously.7 Briefly, mid-logarithmic phase cultures of R6 were diluted 1:20 in
competence medium [Todd–Hewitt broth (Oxoid, Basingstoke, UK) con-
taining 1 mM calcium chloride (Sigma Aldrich Ltd, Dorset, UK), 0.2% BSA
(Sigma Aldrich Ltd, Dorset, UK) and 100 ng/mL competence-stimulating
peptide 1 (CSP1; Mimotopes, Clayton, Victoria, Australia)]. For whole-
genome transformation, genomic DNA from the donor strain was added
to a final concentration of 0.2 mg/L to aliquots of the competent cell sus-
pension. For transformation with PCR amplimers, 20 mL of purified PCR
Table 1. Bacterial strains used in this study
Strain Description Reference
R6 unencapsulated WT strain, ATCC BAA255 27
M168 reserpine-resistant mutant derived from M4 7
M184 reserpine-resistant mutant derived from R6 7
M87 clinical isolate from MRL Pharmaceutical Services 28
M101 clinical isolate from MRL Pharmaceutical Services 28
M505 R6 recipient transformed with M101 DNA, selected
on 8 mg/L ethidium bromide
this study
M506 R6 recipient transformed with M187 DNA, selected
on 8 mg/L ethidium bromide
this study
M507 R6 recipient transformed with M174 DNA, selected
on 8 mg/L ethidium bromide
this study
M511 R6 containing pBAV1K-gfp82 vector this study
M512 R6 containing construct pBAV1K-gfp82-WT this study
M513 R6 containing construct pBAV1K-gfp82-v101 this study
M514 R6 containing construct pBAV1K-gfp82-v101c this study
M517 R6 containing construct pBAV1K-gfp82-v168 this study
M518 R6 containing construct pBAV1K-gfp82-v168c this study
M515 R6 containing construct pBAV1K-gfp82-v87 this study
M516 R6 containing construct pBAV1K-gfp82-v87c this study
Table 2. Primers and DNA oligonucleotide used in this study
Target Forward primer Reverse primer
Primer pair
1 patA TCTTGCTCAGTCCATCATCGAA-TATA CCGCTGTGGATTAGTTCATTTCC
2 patB AGAATCCAGTCCAGCGAAAGCT GAAAGAACGACCAGATGTTCCAAT
3 patA first half TCTTGCTCAGTCCATCATCGAA-TATA CAGCATCGGTTCCTTGTC
4 patA second half CAGATGAAGAGTTGGTTGGA CCGCTGTGGATTAGTTCATTTCC
5 patA promoter GATAGGGCAGAAGAGCATCC GATAACGCGGTTGCAGAAGT
6 patA qRT–PCR TCTTAGGCGCCCTCCTTACT ATAGGCTGCGAGGACAAC
7 patB qRT–PCR AGAAATGTGACGCTGGCTCT TTCTGCTGGAGGTTGGTGT
8 guaA qRT–PCR GCGCTTCGTCAGAATAAACC AGTCCTTGCCAGTGACCTTC
9 spr1886 qRT–PCR GGATTGGGAATCGTTTAGGG AGAATCCAGTCCAGCGAAAG
10 hexA qRT–PCR TGTCTAGTGTGCCACGGATT CGCTGCGCTAATCAAACTCT
11 PBAV1K-gfp82 cloning site TAGTATCGACGGAGCCGATT TGTGCCCATTAACATCACCA
DNA oligonucleotide
WT patA upstream region taagaattcaaccaagactcactagttaatctagctgtatcaaggagacttctttgacaattctccacttttttgcta
gaataacatcacacaaacagaatgaaaaggagctgacgcattgtcgctcccttttgtctattttttctagaaag
Bold and underlined text represents restriction enzyme cleavage sites.
Baylay and Piddock
2 of 10
 at U
niversity of Birm
ingham
 on January 19, 2015
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
amplimer was added to 500 mL of cell suspension. Transformation reac-
tions were incubated for 3 h at 378C, then 20 and 200 volumes were
spread onto agar plates containing 8 mg/L ethidium bromide. Viable
counts were determined in parallel to allow estimation of the transform-
ation frequency.
Illumina sequencing and data analysis
Illumina whole-genome sequencing was carried out by Genepool
(Edinburgh, UK) according to standard protocols to give 100 bp paired-end
reads. Reads were mapped against the published R6 genome sequence
(GenBank accession number NC_003098) using Bowtie214 using the
–very-sensitive-local setting, and a consensus pileup was generated
using mpileup in Samtools (version 0.1.18).15 Sets of putative SNPs and
small indels were generated using BCFtools (version 0.1.17-dev).15
Susceptibility of S. pneumoniae to antibiotics and dyes
The MICs of ciprofloxacin, norfloxacin and ethidium bromide were deter-
mined using the standardized agar doubling dilution method according
to the BSAC.16
Ethidium bromide accumulation
Intracellular accumulation of ethidium bromide was measured by moni-
toring fluorescence over time, as follows. Logarithmic-phase bacterial cul-
tures were pelleted by centrifugation at 2200 g and resuspended in PBS
(Life Technologies, cat. no. 14040-133; 2160 mg/L Na2HPO4, 8000 mg/L
NaCl, 200 mg/L KH2PO4, 200 mg/L KCl, 100 mg/L MgCl2 and 100 mg/L
CaCl2). Cell suspensions were adjusted to an OD660 of 0.1 with fresh PBS,
and a 100-cell suspensionwas added in triplicate to a blackmicrotitre tray.
Fluorescence was measured at excitation and emission wavelengths of
530 and 600 nm, respectively, using a FLUOstar Optima plate reader
(BMG Labtech, Aylesbury, UK) every 2 min for a total of 30 min. A final con-
centration of 100 mM ethidium bromide was added to each well by injec-
tion on the second cycle of measurement.
qRT–PCR
Total RNA was extracted from three biological replicates of logarithmic-
phase cultures of each test strain using a Promega SV Total RNA
Isolation kit according to the manufacturer’s instructions (Promega,
Southampton, UK). RNA and contaminating DNA concentrations were
measured using a Qubit fluorimeter according to the manufacturer’s
instructions (Life Technologies, Paisley, UK). Residual DNA contamination
was removed by treatment with Turbo DNase (Life Technologies), and
cDNA was generated using Superscript III reverse transcriptase (Life
Technologies) following the first-strand synthesis protocol supplied by
the manufacturer. Expression of patA, patB, spr1886 and guaAwas mea-
sured relative to expression of rpoB by SYBR Green Quantitative real-time
(qRT) PCR. Reactions consisted of 12.5 mL IQ SYBR Green Supermix
(Bio-Rad, Hemel Hempstead, UK), 375 nM each of forward and reverse pri-
mers and 1 mL cDNA in a 25 mL reaction. Real-time PCR was carried out
using a Bio-Rad CFX96 thermal cycler with the following protocol: 3 min
at 958C, followed by 40 cycles of 10 s at 958C and 30 s at 54.58C.
Expression values were calculated using the Pfaffl method.17
patA expression reporter plasmid construction and
GFP assay
To generate plasmid pBAV1K-gfp82, plasmids pBAV1K-T5-gfp18 and
pMW8219 were digestedwith EcoRI and PstI (Thermo Scientific) and diges-
tion products separated by agarose gel electrophoresis. The 2800 bp
plasmid backbone of pBAVK1K-T5-gfp and the 824 bp band corresponding
to the gfp gene of pMW82were extracted using a Qiagen gel extraction kit
according to the manufacturer’s instructions. The DNA fragments were
ligated using QuickStick ligase (Bioline) and used to transform E. coli
Top10 cells (Life Technologies). Transformants were selected on 50 mg/L
kanamycin. To remove DNA methylation for subsequent digestions,
extracted plasmids were transformed into E. coli JM110 cells and
re-purified.
To clone the patA promoter into pBAV1K-gfp82, giving pBAV1K-
gfp82-WT, a 144 bp DNA fragment was synthesized by GeneArt (Life
Technologies) that covered the region from 12 to 146 bp upstream of
the patA start codon and incorporated a 5′ EcoRI site and a 3′ XbaI site.
The promoter fragment was digested with EcoRI and XbaI, purified
using a QIAquick PCR purification kit (Qiagen) and combined in a 100:1
ratio with pBAV1K2 DNA linearized with XbaI and EcoRI. The DNA frag-
ments were ligated with QuickStick ligase and used to transform E. coli
Top10 cells. Transformants were selected on 50 mg/L kanamycin and
screened for successful incorporation of the insert by PCR with primer
pair 11.
Plasmid DNAwas extracted from E. coli cells using a QIAquick Miniprep
Kit according to the manufacturer’s instructions, and 20 mL of each plas-
mid preparation was used to transform S. pneumoniae R6 as described
above. Successful transformants were selected on plates containing
100 mg/L kanamycin.
To measure expression of patA from the reporter construct, stationary-
phase cultures of R6 containing pBAV1K-gfp82 constructs were diluted to
an OD600 of 0.01 in BHI broth, and 200 mL of diluted culture was added in
duplicate to a black microtitre tray with a clear base (Corning). Cultures
were incubated in a Fluostar Optima at 378C for 12 h, and simultaneous
fluorescence (excitation wavelength 492 nm, emission wavelength
520 nm) and absorbance (600 nm) measurements were taken every
3 min. Absorbance and fluorescence values at each timepoint were calcu-
lated as the average of three biological replicates.
RNA structure prediction
Free energies of folding of RNA structures were predicted computationally
using the RNAfold program from the Vienna RNA suite.20
Results
Genetic determinants causing fluoroquinolone resistance
and patAB up-regulation could be transferred into an
antibiotic-susceptible strain by a single round of
transformation
Laboratory mutants and clinical isolates of S. pneumoniae that
constitutively overexpress patAB have been described previ-
ously,7,9,11,12,21 but the mechanism has not been identified. Two
recent whole-genome sequencing publications described a G–T
mutation 46 bp upstream of patA associated with fluoroquinolone
resistance.9,11 In this study, we investigated the cause of constitu-
tive patAB overexpression in two further fluoroquinolone-resistant
clinical isolates and a laboratory mutant. The two clinical isolates,
M101 and M87, were chosen from a set of previously described clin-
ical isolates with elevated patAB expression.21,22 The third strain
investigated was M168, a laboratory-selectedmutant of type strain
NCTC7465, selected for resistance to the efflux inhibitor reserpine.7
In the case of the laboratory-selected mutants, mutations
causing the desired phenotype could be identified by a whole-
genome re-sequencing approach: sequencing of the mutant
and detection of polymorphisms with respect to the genome
PatAB overexpression caused by attenuator mutations
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sequence of an isogenic parental strain. However, for the two clin-
ical isolates investigated in this study, antibiotic-susceptible par-
ental strains were not available for comparison so this approach
could not be used. However, viable transformants could be
selected on ethidium bromide (8 mg/L), a known PatAB substrate,
when the unencapsulated laboratory strain R6 was transformed
with high-molecular weight DNA extracted from either M101 or
M87 (giving R6M101 and R6M87, respectively). Although a parental
strain was available for the laboratory-selected strain M168, the
same approach of whole-genome transformation into R6 (giving
R6M168) was followed for consistency.
In all three cases, a single round of transformation was suffi-
cient to select transformants with an ethidium bromide MIC of 32
or 64 mg/L, three to four dilutions higher than that of R6. The eth-
idium bromide MICs were slightly higher than those for the donor
strains, possibly reflecting the expression of patAB in a different
genetic background.
To confirm that the selection for ethidium bromide resistance
correlated with the transfer of mutations causing patAB over-
expression, we carried out three checks. Firstly, antibiotic suscep-
tibility profiles were determined by agar doubling dilution MIC
(Table 3). All three transformants were less susceptible to cipro-
floxacin, norfloxacin and ethidium bromide compared with R6,
and this was reversed in the presence of sodium orthovanadate,
an inhibitor of ABC transporters. The susceptibility of R6 to all three
agents was also increased slightly in the presence of sodium
orthovanadate, most likely due to inhibition of basal levels
of the PatAB expressed by the R6 strain. Secondly, the intracellular
accumulation of ethidium bromide was measured by fluores-
cence assay. Transformants showed a 20%–30% reduction in ac-
cumulation of ethidium bromide compared with R6 (Figure 1a).
A previously described strain, M184,7 which expresses patAB at a
very high level (.100-fold higher than R6, data not shown) was
used as a positive control.
Finally, expression of patA and patB was measured directly by
qRT–PCR. Expression of both patA and patB was significantly
higher in R6M168, R6M101 and R6M87 than in R6 (Figure 1b and c
and Table 4; P,0.05). Taken together, these results made us con-
fident that mutations causing patAB overexpression had been
successfully transferred using the whole-genome transformation
approach.
Sequencing of transformants revealed mutations in a
Rho-independent terminator upstream of patA
To identify mutations causing patAB overexpression in the three
transformants, whole genomic DNA was extracted from strains
Table 3. MICs of PatAB substrates for transformants R6M168, R6M101
and R6M87
Strain
MIC (mg/L)
CIP CIP+Ort NOR NOR+Ort EtBr EtBr+Ort
R6 1 0.5 4 1 4 ,1
M184 4 0.5 32 2 64 ,1
R6M168 2 0.5 16 2 32 ,1
R6M101 4 0.5 32 2 64 ,1
R6M87 4 0.5 32 2 64 ,1
CIP, ciprofloxacin; NOR, norfloxacin; EtBr, ethidium bromide; Ort, 50 mM
sodium orthovanadate.
Bold numbers indicate MIC values that are two or more dilutions higher
than those for R6.
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Figure 1. Confirmation of patAB overexpression phenotype in transformants
R6M168, R6M101 and R6M87. (a) Fluorescence due to intracellular accumulation
of ethidium bromide following 10 min of incubation with 100 mM ethidium
bromide. Bars and error bars represent averages and standard deviations of
three biological replicates. *Accumulation significantly lower than R6;
P,0.05, one-tailed Student’s t-test. A previously described strain, M184,
was used as a positive control. (b) Representation of the patAB genetic
locus. (c) Expression of patA, patB and neighbouring genes in R6 and
transformants R6M168, R6M101 and R6M87 measured by qRT–PCR compared
with rpoB. Bars represent average expressions relative to R6 from three
biological replicates and are shaded by gene as in panel (b). Error bars
represent standard deviations of three biological replicates. *Expression
significantly different from R6; P,0.05, two-tailed Student’s t-test.
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R6, R6M168, R6M101 and R6M74 and sequenced using Illumina tech-
nology. Reads were aligned to the published R6 genome sequence
(NC_003098) and SNPs detected. The laboratory stock of R6 used
for our experiments differed from the published R6 genome
sequence by 58 mutations (data not shown). These mutations
were also observed in the three transformants and were dis-
carded from further analysis. Regions of the transformant gen-
omes where recombination had occurred between the donor
and recipient genomes could be identified as clusters of SNPs rela-
tive to R6. Clusters were loosely defined as regions of the genome
where the number of SNPs in a 5 kb sliding window was consist-
ently greater than two. A single recombination event was
observed in R6M168, occurring in the region of the genome that
contains patAB. Multiple recombination events were observed in
R6M101 and R6M87 (14 and 24, respectively). In both of these
strains, however, there was a recombinant region in the vicinity
of the patA and patB genes, as observed in R6M168 (Figure 2a).
The recombinant regions that encompassed the patAB genes
were examined inmore detail. Theminimumsizes of the recombin-
ant regions (naively defined as the distance between the first and
last SNP in the cluster) ranged between 9.7 and 12.2 kb. The clus-
ters consisted of 70 SNPs in R6M168, 64 in R6M101 and 62 in R6M87. To
distinguish mutations causing patAB overexpression from natural
polymorphisms between the donor strains and the recipient, we
transformed R6 with targeted PCR amplimers from this region in
M168, M101 andM87, and selected for ethidium bromide-resistant
transformants (Figure 2b). We focused on the patA and patB genes
themselves due to the considerable overlap of non-contiguous
recombinant regions covering these genes in the three transfor-
mants. We obtained ethidium bromide-resistant transformants
using an amplimer corresponding to the patA gene from all three
donor strains. No ethidium bromide-resistant transformants were
obtained with amplimers corresponding to patB. Transformation
with further PCR amplimers corresponding to smaller segments
of patA localized themutations conferring ethidium bromide resist-
ance to a region between genomic positions 1865645 and
1865963, corresponding to the intergenic region between patA
and the upstream gene hexA in all three donor strains.
The region identified was examined in more detail. In each
transformant, the identified region contained one SNP relative
to R6. Relative to the start codon of patA, these were C(233)T
in R6M168, A(247)C in R6M101 and G(246)A in R6M87. A putative
attenuator structure, consisting of a Rho-independent terminator,
anti-terminator and anti-anti-terminator, was predicted up-
stream of patA using the Ribex server.22 The three identified
mutationswere all locatedwithin the terminator loop of this puta-
tive structure (Figure 2c). Themutation found in R6M87 occurred in
the same position as the G–T mutation identified in the two pre-
vious studies;9,11however, the nucleotide substitution in our strain
was G–A.
Identified mutations are predicted to reduce the stability
of the Rho-independent terminator by disrupting base
pairing
The G–T mutation identified previously was predicted to reduce
the stability of terminator loop folding, leading to increased tran-
scription of the downstream gene. To predict whether our muta-
tions were likely to have the same effect, we used the RNAfold
program from the Vienna RNA suite to predict the RNA structure
(Figure 3a) and determine the folding energy of WT and mutated
terminator structures (Figure 3b). Introduction of any of the three
mutations identified in our transformants increased the predicted
free energy of folding of the terminator structure relative to WT
(Figure 3b). The different mutations were predicted to destabilize
the terminator to differing degrees. There was a strong positive
correlation between predicted folding energy of the terminator
and levels of expression of both patA (R2¼0.98) and patB
(R2¼0.98) as measured by qRT–PCR (Figure 3c).
Mutations disrupting terminator structure lead to
increased transcription of a downstream GFP reporter
It was predicted that reduced stability of the terminator loop
would increase transcription of patAB, by increasing transcrip-
tional read-through into the patA coding sequence.11 However,
this had not been experimentally demonstrated. To investigate
this, we synthesized four DNA fragments corresponding to the
patA upstream region (2146 to 213 bp), flanked by restriction
sites. One fragment corresponded to the WT (R6) sequence, and
the remaining three introduced the mutations C(233)T (v168),
A(247)C (v101) and G(246)A (v87). These were cloned upstream
of a promoter-less GFP allele in a plasmid named pBAV1K-gfp82,
derived from pBAV1K-t5-gfp (construction described in the
Materials and methods section). The resulting constructs were
transformed into R6 cells and transformants selected using
100 mg/L kanamycin. Fluorescence from each construct was
measured during growth of the strains in BHI broth. Compared
with a strain carrying pBAV1K-gfp82 empty vector, the
pBAV1K-gfp82-WT construct produced consistently higher fluor-
escence throughout the growth cycle (Figure 4). Introduction of
the terminator mutations (constructs pBAV1K-gfp82-v168,
pBAV1K-gfp82-v101 and pBAV1K-gfp82-v87) resulted in a signifi-
cant 1.5- to 3-fold increase in fluorescence in all three cases after
2.5, 3.5 and 5.5 h of growth, respectively, representing late-log,
stationary and late-stationary phases, respectively (Figure 4;
P,0.05, two-tailed Student’s t-test).
Restoration of terminator stem–loop stability leads to a
reduction in transcription of the downstream reporter
The mutations investigated were predicted to cause patAB over-
expression by disrupting the base pairing of the terminator
stem–loop structure. Restoration of this base pairing should
therefore restore termination and reduce transcription of the
Table 4. Expression of patA and patB in transformants R6M168, R6M101 and
R6M87 compared with R6
Fold change in expression compared with R6
patA patB
average SD average SD
R6M168 3.3 0.5 3.5 0.7
R6M101 4.7 0.1 5.7 0.4
R6M87 6.4 1.4 8.2 1.9
SD, standard deviation of three biological replicates.
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downstream gene. To investigate this prediction, for each mutant
terminator we synthesized a further DNA fragment in which we
attempted to re-form the predicted WT terminator structure by
mutating the opposing base in the stem–loop such that
Watson2Crick base pairing was restored (Figure 3a). This gave con-
structs pBAV1K-gfp82-v168c [C(233)T and G(243)A], pBAV1K-
gfp82-v101c [A(247)C and T(230)G] and pBAV1K-gfp82-v87c
[G(246)A and C(231)T]. In the case of v101c, mutating the oppos-
ing base in the structure resulted in a reduction of the predicted
folding energy of the terminator (determined by RNAfold) back to
below WT levels (Figure 3b). However, this was not the case for
v168c and v87c, where mutation of the opposing base did not sub-
stantially reduce folding energy. Our model of the RNA folding was
very simplistic and there may be further stabilizing interactions
beyond simple base pairing that we did not take into account.
Consistent with the predictions of folding energy, GFP fluorescence
from pBAV1K-gfp82-v101c was significantly reduced compared
with pBAV1K-gfp82-v101 at all tested growth stages (Figure 4a;
P,0.05), and instead was either the same as or significantly
lower than WT fluorescence. Fluorescence from pBAV1K-gfp82-
v168c and pBAV1K-gfp82-v87c was not reduced by the attempt
to restore base pairing, and remained significantly higher than WT
at all tested growth stages (Figure 4b and c; P,0.05).
Discussion
In this study, we have identified three novel SNPs causing
up-regulation of patAB in S. pneumoniae. All three mutations
were located in a Rho-independent transcriptional terminator
located directly upstream of patA. Combined with the G2Tmuta-
tion identified in two previous studies,9,11 four mutations have
now been observed in this terminator structure, providing strong
support for the hypothesis that this terminator structure is import-
ant for suppression of patAB expression and consequent fluoro-
quinolone resistance.
Rho-independent terminators consist of an RNA stem–loop
structure that arrests progression of the transcription complex,
followed by a uracil-rich region that promotes dissociation
of the polymerase from the DNA.23 Mutations disrupting the
stem–loop structure are therefore predicted to reduce polymer-
ase pausing, and therefore dissociation, promoting continued
transcription of the downstream gene. This hypothesis was previ-
ously proposed to explain the observed increase in patAB expres-
sion in terminator mutants;11 however, this had not been
experimentally demonstrated. Here, we have used transcriptional
fusion of the patA upstream region with a GFP reporter to demon-
strate that terminator mutations do lead to increased transcrip-
tional read-through into a downstream gene.
Fluorescence from the pBAV1K-gfp82-WT construct was con-
sistently higher than from the empty vector at all growth stages
tested. This suggests that patAB is transcribed at a basal level
throughout growth. Disruption of the terminator stem–loop by
all three mutations tested then increased this further. Two obser-
vations indicated that the stem–loop structure is important for
transcriptional control. Firstly, there was a very strong correlation
between predicted minimum free energy of the WT and mutant
terminator structures and patAB expression level. Secondly, res-
toration of the stem–loop structure in the v101 variant by muta-
tion of the opposing base in the structure reduced fluorescence
back to WT levels. Taken together, these results suggest that
the mutations increase downstream gene expression by reducing
Rho-independent termination, as opposed to another mechan-
ism, such as mutation of a transcription factor binding site.
It has previously been observed that isolates overexpressing
patAB can be selected easily by exposure to the fluoroquinolone
antibiotic ciprofloxacin or the efflux inhibitor reserpine.7,24 As
demonstrated here, patAB overexpression can be conferred by
any one of a number of mutations that disrupt the upstream ter-
minator, which may explain how patAB-overexpressing mutants
can be selected so reliably.
Disruption of the patA upstream terminator provides an
explanation for selection of constitutive patAB expression on
exposure to antibacterial agents. However, it does not explain
the inducible patAB expression on exposure to fluoroquinolones
or DNA-damaging agents that has been previously observed.
Here, we observed that the Rho-independent transcriptional ter-
minator is predicted to be part of a transcriptional attenuator,
consisting of terminator, anti-terminator and anti-anti-termin-
ator stem–loops. Transcriptional attenuation is a prevalent regu-
latory strategy in Gram-positive bacteria.25 Transcriptional
attenuators are RNA leader sequences that can fold into two or
more mutually exclusive stem–loops, one of which is a
Rho-independent terminator, and this folding can be influenced
by a variety of regulatory signals.26 Although it was not investi-
gated in this study, it is conceivable that the presence of fluoroqui-
nolones or DNA damage may result in induction of patAB
expression via a regulatory signal that reversibly disrupts the
patA upstream terminator. Recently, a similar transcriptional
attenuator was found to be involved in up-regulation of the
BmrCDABC transporter in Bacillus subtilis in response to ribosome-
targeting antibiotics.27 Similarly, expression of another B. subtilis
ABC transporter gene associated with antibiotic resistance,
bmrA, has been shown to be increased by an upstream mutation
that increases mRNA stability.28 When combined with our results,
these findings raise the intriguing possibility that transcriptional
attenuation may be a common method of control of ABC trans-
porter family efflux pumps in Gram-positive bacteria.
In this study, we located the mutations causing patAB overex-
pression using a whole-genome transformation approach that
exploited the natural transforming ability of S. pneumoniae. This
Figure 2. Locations of putative recombinant regions in transformants identified bywhole-genome sequencing. (a) Recombinationsmapped onto the R6
genome. Rings are numbered from outside to inside. Rings 1 and 2 represent R6 coding sequences encoded on the plus and minus strand, respectively.
Rings 3, 4 and 5 represent putative recombinant regions in R6M101, R6M87 and R6M168, respectively. The region containing the patA and patB genes is
indicated by the dashed box. (b) Extents of PCR amplimers from R6M101, R6M87 and R6M168 used for targeted transformation of R6 cells to determine
the location of mutations causing patAB overexpression. Solid, filled boxes represent amplimers that produced ethidium bromide-resistant
transformants. Dashed boxes represent amplimers for which no ethidium bromide-resistant transformants were obtained. (c) DNA sequence
upstream of patA, with locations of mutations identified in R6M101, R6M87 and R6M168 indicated (*). The transcriptional attenuator predicted by Ribex,
consisting of terminator (solid lines), anti-terminator (shaded text) and anti-anti-terminator (dashed lines) loops, is also indicated. The start of the patA
coding sequence is shown in capital letters.
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approach was similar to that used by Billal et al.9 to separate
mutations causing linezolid resistance from bystander mutations.
We used natural polymorphisms between the donor strains and
the R6 recipient as a marker to distinguish regions of the genome
that have undergone recombination, and therefore may contain
mutations of interest. As a by-product of this, we observed pri-
mary and secondary recombinations in the same cell, as recently
described by Croucher et al.11 We also saw multiple contiguous
recombinations from the same piece of DNA, as was also
described by Croucher et al.11 In this study, all three mutations
were ultimately found to be located in the upstream region of
patA, so they could have been discovered by other methods.
However, themethod used here has the potential to locate causa-
tive mutations anywhere in the genome, such as in a regulator
encoded elsewhere. Due to recent improvements in whole-
genome sequencing technology, meaning that many bacterial
strains can be multiplexed in a single Illumina lane for a relatively
low cost, this method could therefore be used to screen a larger
library of patAB-overexpressing isolates to identify other compo-
nents of the patAB regulatory pathway.
v101: A->C 3¢
5¢
u
u
a u
u
u
u
uuc
c
c
u
c
c
u
u
u
a
c
a
g
u c
g
g
g
a
c
g
g
g
g
c
v87: G->A
v168c: G->A
v101c: T->G
v87c: C->T
v168c: C->T
v101
v168
v87
M
FE
 o
f f
ol
di
ng
0
(a) (b)
–5
–10
–15
0
–5
–10
–15
0
–5
–10
–15
0 20 40
Transcript length (nt)
60 80 100
10
8
(c)
6
4
Ex
pr
es
si
on
 re
la
tiv
e 
to
 R
6
2
0
–10 –8
Predicted MFE of folding
R6
R6
v168
v168
v101
v101
v87
v87
–6 –4
Figure 3. Structure of Rho-independent transcriptional terminator predicted by the RNAfold program from the Vienna RNA suite. (a) Predicted
terminator structure. Mutations incorporated into pBAV1K-gfp82 constructs v101, v168 and v87 are indicated by solid boxes. Further mutations
introduced in constructs v101c, v168c and v87c to attempt to restore base pairing are indicated by dashed boxes. (b) Folding energy of nascent
patA transcript, predicted by RNAfold for WT (solid lines), mutant (v101, v168 and v87; dashed lines) and complemented (v101c, v168c and v87c;
dotted lines) leader sequences. The nascent transcript was extended stepwise from the predicted patA transcription start site 67 bp upstream of the
patA start codon. (c) Correlation between predicted stability of the patA transcript at 67 nt and expression of patA (solid line) and patB (dashed line)
relative to R6 as measured by qRT–PCR.
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Figure 4. Fluorescence measured from pBAV1K-gfp82 reporter plasmid
containing WT and mutant patA leader sequences during late-log (2.5 h),
stationary (3.5 h) and late-stationary (5.5 h) phases of growth. Bars
represent the fluorescence of pBAV1K-gfp82-WT and (a) v101 and v101c,
(b) v168 and v168c and (c) v87 and v87c, adjusted to a standard OD600 of
0.5, relative to the fluorescence of empty pBAV1K-gfp82 vector. Error bars
represent the standard deviation of three biological replicates. *Fluorescence
significantly different from WT; P,0.05, two-tailed Student’s t-test.
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